Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet

Maurizio Delvecchio; Clara Zecchino; Maria Felicia Faienza; Angelo Acquafredda; Fabrizio Barbetti; Luciano Cavallo

doi:10.1016/j.diabres.2009.02.024

Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet

Diabetes Res Clin Pract. 2009 Jun;84(3):332-4. doi: 10.1016/j.diabres.2009.02.024. Epub 2009 Apr 3.

Authors

Maurizio Delvecchio¹, Clara Zecchino, Maria Felicia Faienza, Angelo Acquafredda, Fabrizio Barbetti, Luciano Cavallo

Affiliation

¹ Department of Develpmental Age, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. m.delvecchio@email.it

PMID: 19345438
DOI: 10.1016/j.diabres.2009.02.024

Abstract

A girl with celiac disease and KCNJ11 mutation was transferred to glibenclamide when 19.8 years old. When her compliance to the gluten free diet worsened, her metabolic control deteriorated. Since glibenclamide is absorbed in the intestine, its absorption seems to be impaired by chronic malabsorption, increasing the risk of hyperglycaemia.

Publication types

Case Reports

MeSH terms

Amino Acid Substitution
Autoantibodies / blood
Diabetes Mellitus / diet therapy
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / psychology
Diet, Gluten-Free*
Female
Glyburide / pharmacokinetics
Glyburide / therapeutic use*
Glycated Hemoglobin / metabolism
Humans
Hypoglycemic Agents / pharmacokinetics
Hypoglycemic Agents / therapeutic use*
Infant, Newborn
Insulin / therapeutic use
Intestinal Absorption
Patient Compliance
Potassium Channels, Inwardly Rectifying / genetics*
Sulfonylurea Compounds / pharmacokinetics
Sulfonylurea Compounds / therapeutic use*
Transglutaminases / immunology
Young Adult

Substances

Autoantibodies
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin
Kir6.2 channel
Potassium Channels, Inwardly Rectifying
Sulfonylurea Compounds
Transglutaminases
Glyburide